Amyloid : one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease

被引:75
作者
Clark, I. A. [1 ]
Vissel, B. [2 ]
机构
[1] Australian Natl Univ, Biomed Sci & Biochem, Res Sch Biol, Canberra, ACT 2601, Australia
[2] Garvan Inst, Neurodegenerat Res Grp, Sydney, NSW, Australia
关键词
TUMOR-NECROSIS-FACTOR; POSTOPERATIVE COGNITIVE DYSFUNCTION; MOBILITY GROUP BOX-1; FLUID MITOCHONDRIAL-DNA; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; FACTOR-ALPHA; TNF-ALPHA; CEREBROSPINAL-FLUID; A-BETA;
D O I
10.1111/bph.13181
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This review concerns how the primary inflammation preceding the generation of certain key damage-associated molecular patterns (DAMPs) arises in Alzheimer's disease (AD). In doing so, it places soluble amyloid (A), a protein hitherto considered as a primary initiator of AD, in a novel perspective. We note here that increased soluble A is one of the proinflammatory cytokine-induced DAMPs recognized by at least one of the toll-like receptors on and in various cell types. Moreover, A is best regarded as belonging to a class of DAMPs, as do the S100 proteins and HMBG1, that further exacerbate production of these same proinflammatory cytokines, which are already enhanced, and induces them further. Moreover, variation in levels of other DAMPs of this same class in AD may explain why normal elderly patients can exhibit high A plaque levels, and why removing A or its plaque does not retard disease progression. It may also explain why mouse transgenic models, having been designed to generate high A, can be treated successfully by this approach.
引用
收藏
页码:3714 / 3727
页数:14
相关论文
共 210 条
[1]  
AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345
[2]   THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: CATALYTIC RECEPTORS [J].
Alexander, Stephen P. H. ;
Benson, Helen E. ;
Faccenda, Elena ;
Pawson, Adam J. ;
Sharman, Joanna L. ;
Spedding, Michael ;
Peters, John A. ;
Harmar, Anthony J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2013, 170 (08) :1676-1705
[3]   THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: ENZYMES [J].
Alexander, Stephen P. H. ;
Benson, Helen E. ;
Faccenda, Elena ;
Pawson, Adam J. ;
Sharman, Joanna L. ;
Spedding, Michael ;
Peters, John A. ;
Harmar, Anthony J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2013, 170 (08) :1797-1867
[4]   Up-regulation of miRNA-146a in progressive, age-related inflammatory neurodegenerative disorders of the human CNS [J].
Alexandrov, Peter N. ;
Dua, Prerna ;
Lukiw, Walter J. .
FRONTIERS IN NEUROLOGY, 2014, 5
[5]   Systemic release of high mobility group box 1 protein during severe murine influenza [J].
Alleva, Lisa M. ;
Budd, Alison C. ;
Clark, Ian A. .
JOURNAL OF IMMUNOLOGY, 2008, 181 (02) :1454-1459
[6]   High mobility group box 1 (HMGB1) protein: possible amplification signal in the pathogenesis of falciparum malaria [J].
Alleva, LM ;
Yang, H ;
Tracey, KJ ;
Clark, IA .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2005, 99 (03) :171-174
[7]  
Alvarez-Arellano Lourdes, 2014, World J Gastrointest Pathophysiol, V5, P400, DOI 10.4291/wjgp.v5.i4.400
[8]   HMGB1 in sepsis [J].
Andersson, U ;
Tracey, KJ .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2003, 35 (09) :577-584
[9]   High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes [J].
Andersson, U ;
Wang, HC ;
Palmblad, K ;
Aveberger, AC ;
Bloom, O ;
Erlandsson-Harris, H ;
Janson, A ;
Kokkola, R ;
Zhang, MH ;
Yang, H ;
Tracey, KJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (04) :565-570
[10]  
[Anonymous], TODAYS LIFE SCI